MediXall Group Statistics
Total Valuation
MediXall Group has a market cap or net worth of 734,615. The enterprise value is 1.31 million.
| Market Cap | 734,615 |
| Enterprise Value | 1.31M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
MediXall Group has 209.89 million shares outstanding.
| Current Share Class | 209.89M |
| Shares Outstanding | 209.89M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +16.88% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.41 |
| PB Ratio | -0.20 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.51 |
| Interest Coverage | -2.43 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -363.77% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 55.02% |
| Weighted Average Cost of Capital (WACC) | 269.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 7 |
| Asset Turnover | 0.90 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.26% in the last 52 weeks. The beta is 72.94, so MediXall Group's price volatility has been higher than the market average.
| Beta (5Y) | 72.94 |
| 52-Week Price Change | -10.26% |
| 50-Day Moving Average | 0.25 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 41.31 |
| Average Volume (20 Days) | 6,972 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, MediXall Group had revenue of 304,336 and -2.43 million in losses. Loss per share was -0.02.
| Revenue | 304,336 |
| Gross Profit | -664,918 |
| Operating Income | -1.97M |
| Pretax Income | -2.16M |
| Net Income | -2.43M |
| EBITDA | -1.94M |
| EBIT | -1.97M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 31,916 in cash and 607,925 in debt, with a net cash position of -576,009 or -0.00 per share.
| Cash & Cash Equivalents | 31,916 |
| Total Debt | 607,925 |
| Net Cash | -576,009 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -3.62M |
| Book Value Per Share | -0.02 |
| Working Capital | -3.75M |
Cash Flow
| Operating Cash Flow | -1.20M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 29,950 |
| Net Borrowing | 970,655 |
| Free Cash Flow | -1.20M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | -218.48% |
| Operating Margin | -645.91% |
| Pretax Margin | -710.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MediXall Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.83% |
| Shareholder Yield | -13.83% |
| Earnings Yield | -330.92% |
| FCF Yield | -163.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MediXall Group has an Altman Z-Score of -296.68 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -296.68 |
| Piotroski F-Score | 4 |